Why the study?
Are there disparities in the stage at presentation of hepatocellular carcinoma among disaggregated AANHPI subgroups compared to Non-Hispanic White patients?
Population
Patients with hepatocellular carcinoma (HCC) in the SEER program (17 registries, 2000–2022)
Comparison
Disaggregated Asian American, Native Hawaiian… vs Non-Hispanic White (NHW) patients
Design
Cohort
Key result
Compared to Non-Hispanic Whites, Chinese (AOR 1.17; 95% CI 1.10-1.25) and Vietnamese patients had higher odds of advanced-stage HCC, while Filipino, Laotian, and Pacific Islanders had lower odds.
Authors
Loading...
Disaggregation of AANHPI populations reveals significant heterogeneity in HCC stage at presentation, highlighting the need for subgroup-specific surveillance strategies.
Observational
Yes
Are there disparities in the stage at presentation of hepatocellular carcinoma among disaggregated AANHPI subgroups compared to Non-Hispanic White patients?
Effect estimate: AOR 1.17 (95% CI 1.10-1.25)
p-value: p=<0.001
Disaggregation of AANHPI populations reveals significant heterogeneity in HCC stage at presentation, highlighting the need for subgroup-specific surveillance strategies.
Doan et al. (2026) conducted an observational in Hepatocellular carcinoma. Race and ethnicity (disaggregated AANHPI subgroups) vs. Non-Hispanic White patients was evaluated on Advanced-stage disease at presentation (AOR 1.17, 95% CI 1.10-1.25, p=<0.001). Compared to Non-Hispanic Whites, Chinese (AOR 1.17; 95% CI 1.10-1.25) and Vietnamese patients had higher odds of advanced-stage HCC, while Filipino, Laotian, and Pacific Islanders had lower odds.